Historial de carrera de Robert Goodenow
Antiguos cargos conocidos de Robert Goodenow.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| INOVIO PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2002 | 16/03/2007 |
HUYA Bioscience International LLC
 HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 16/06/2015 | - |
| Presidente | - | - | |
| BAXTER INTERNATIONAL INC. | Corporate Officer/Principal | - | - |
| Aventis, Inc. | Corporate Officer/Principal | - | - |
| SYNDAX PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/03/2007 | - |
| Secretario Corporativo | 01/11/2010 | - |
Formación de Robert Goodenow.
| University of California, Berkeley | Undergraduate Degree |
| Stanford University | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 8 |
Operativa
| Corporate Officer/Principal | 5 |
| Corporate Secretary | 1 |
| Undergraduate Degree | 1 |
Sectorial
| Health Technology | 5 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| INOVIO PHARMACEUTICALS, INC. | Health Technology |
| SYNDAX PHARMACEUTICALS, INC. | Health Technology |
| BAXTER INTERNATIONAL INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
| Aventis, Inc. | |
HUYA Bioscience International LLC
HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Robert Goodenow
- Experiencia
